LGM
SNDX icon

Logos Global Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Logos Global Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-350,000
Closed -$8.33M – 72
2024
Q1 		$8.33M Buy
+350,000
New +$7.81M 0.67% 38

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Logos Global Management's SNDX Position: Q2 2024 in Review

Logos Global Management sold out of Syndax Pharmaceuticals (SNDX) in Q2 2024, closing a stake of 350,000 shares — an estimated $8.33M sold.

Logos Global Management first reported a position in SNDX in Q1 2024 and held it in 1 quarter. The position peaked at $8.33M in Q1 2024. 196 funds tracked by Wall St. Rank hold SNDX as of Q2 2024.

  • Logos Global Management reported no remaining Syndax Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Logos Global Management sold 350,000 Syndax Pharmaceuticals shares in Q2 2024, an estimated $8.33M.
  • Logos Global Management first reported a position in Syndax Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Logos Global Management's Syndax Pharmaceuticals position peaked at $8.33M in Q1 2024.
  • 196 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2024.

Based on Logos Global Management's 13F filing for Q2 2024, filed 14 Aug 2024.